Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults

  1. Flavia Camponovo
  2. Joseph J Campo
  3. Timothy Q Le
  4. Amit Oberai
  5. Christopher Hung
  6. Jozelyn V Pablo
  7. Andy A Teng
  8. Xiaowu Liang
  9. B Kim Lee Sim
  10. Said Jongo
  11. Salim Abdulla
  12. Marcel Tanner
  13. Stephen L Hoffman
  14. Claudia Daubenberger
  15. Melissa A Penny  Is a corresponding author
  1. Swiss Tropical and Public Health Institute, Switzerland
  2. Antigen Discovery Inc, United States
  3. Sanaria Inc, United States
  4. Ifakara Health Institute, United Republic of Tanzania
  5. University of Basel, Switzerland

Abstract

Tanzanian adult male volunteers were immunized by direct venous inoculation with radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum (Pf) sporozoites (PfSPZ Vaccine) and protective efficacy assessed by homologous controlled human malaria infection (CHMI). Serum immunoglobulin G (IgG) responses were analyzed longitudinally using a Pf protein microarray covering 91% of the proteome, providing first insights into naturally acquired and PfSPZ Vaccine-induced whole parasite antibody profiles in malaria pre-exposed Africans. Immunoreactivity was identified against 2,239 functionally diverse Pf proteins, showing a wide breadth of humoral response. Antibody-based immune 'fingerprints' in these individuals indicated a strong person-specific immune response at baseline, with little changes in the overall humoral immunoreactivity pattern measured after immunization. The moderate increase in immunogenicity following immunization and the extensive and variable breadth of humoral immune response observed in the volunteers at baseline suggest that pre-exposure reduces vaccine-induced antigen reactivity in unanticipated ways.

Data availability

All data analyzed during this study are included in the manuscript and supporting files, or sited accordingly when published elsewhere

Article and author information

Author details

  1. Flavia Camponovo

    Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    No competing interests declared.
  2. Joseph J Campo

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Joseph J Campo, is an employee of Antigen Discovery, Inc.
  3. Timothy Q Le

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Timothy Q Le, is an employee of Antigen Discovery, Inc.
  4. Amit Oberai

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Amit Oberai, is an employee of Antigen Discovery, Inc.
  5. Christopher Hung

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Christopher Hung, is an employee of Antigen Discovery, Inc.
  6. Jozelyn V Pablo

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Jozelyn V Pablo, is an employee of Antigen Discovery, Inc.
  7. Andy A Teng

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Andy A Teng, is an employee of Antigen Discovery, Inc.
  8. Xiaowu Liang

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Xiaowu Liang, is an employee of Antigen Discovery, Inc.
  9. B Kim Lee Sim

    Process Development and Manufacturing, Sanaria Inc, Rockville, United States
    Competing interests
    B Kim Lee Sim, This author is affiliated with Sanaria Inc. Sanaria manufactured PfSPZ Vaccine and PfSPZ Challenge.
  10. Said Jongo

    Interventions and Clinical Trials Unit, Bagamoyo Branch, Ifakara Health Institute, Dar es Salam, United Republic of Tanzania
    Competing interests
    No competing interests declared.
  11. Salim Abdulla

    Interventions and Clinical Trials Unit, Bagamoyo Branch, Ifakara Health Institute, Dar es Salam, United Republic of Tanzania
    Competing interests
    No competing interests declared.
  12. Marcel Tanner

    Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    No competing interests declared.
  13. Stephen L Hoffman

    Process Development and Manufacturing, Sanaria Inc, Rockville, United States
    Competing interests
    Stephen L Hoffman, This author is employed by Sanaria. Sanaria Inc. manufactured PfSPZ Vaccine and PfSPZ Challenge. Thus, all authors associated with Sanaria have potential conflicts of interest..
  14. Claudia Daubenberger

    University of Basel, Basel, Switzerland
    Competing interests
    No competing interests declared.
  15. Melissa A Penny

    Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    For correspondence
    melissa.penny@unibas.ch
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4972-593X

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PP00P3_170702)

  • Melissa A Penny

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Camponovo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,558
    views
  • 196
    downloads
  • 18
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Flavia Camponovo
  2. Joseph J Campo
  3. Timothy Q Le
  4. Amit Oberai
  5. Christopher Hung
  6. Jozelyn V Pablo
  7. Andy A Teng
  8. Xiaowu Liang
  9. B Kim Lee Sim
  10. Said Jongo
  11. Salim Abdulla
  12. Marcel Tanner
  13. Stephen L Hoffman
  14. Claudia Daubenberger
  15. Melissa A Penny
(2020)
Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults
eLife 9:e53080.
https://doi.org/10.7554/eLife.53080

Share this article

https://doi.org/10.7554/eLife.53080

Further reading

    1. Epidemiology and Global Health
    2. Evolutionary Biology
    Renan Maestri, Benoît Perez-Lamarque ... Hélène Morlon
    Research Article

    Several coronaviruses infect humans, with three, including the SARS-CoV2, causing diseases. While coronaviruses are especially prone to induce pandemics, we know little about their evolutionary history, host-to-host transmissions, and biogeography. One of the difficulties lies in dating the origination of the family, a particularly challenging task for RNA viruses in general. Previous cophylogenetic tests of virus-host associations, including in the Coronaviridae family, have suggested a virus-host codiversification history stretching many millions of years. Here, we establish a framework for robustly testing scenarios of ancient origination and codiversification versus recent origination and diversification by host switches. Applied to coronaviruses and their mammalian hosts, our results support a scenario of recent origination of coronaviruses in bats and diversification by host switches, with preferential host switches within mammalian orders. Hotspots of coronavirus diversity, concentrated in East Asia and Europe, are consistent with this scenario of relatively recent origination and localized host switches. Spillovers from bats to other species are rare, but have the highest probability to be towards humans than to any other mammal species, implicating humans as the evolutionary intermediate host. The high host-switching rates within orders, as well as between humans, domesticated mammals, and non-flying wild mammals, indicates the potential for rapid additional spreading of coronaviruses across the world. Our results suggest that the evolutionary history of extant mammalian coronaviruses is recent, and that cases of long-term virus–host codiversification have been largely over-estimated.

    1. Cancer Biology
    2. Epidemiology and Global Health
    Chelsea L Hansen, Cécile Viboud, Lone Simonsen
    Research Article

    Cancer is considered a risk factor for COVID-19 mortality, yet several countries have reported that deaths with a primary code of cancer remained within historic levels during the COVID-19 pandemic. Here, we further elucidate the relationship between cancer mortality and COVID-19 on a population level in the US. We compared pandemic-related mortality patterns from underlying and multiple cause (MC) death data for six types of cancer, diabetes, and Alzheimer’s. Any pandemic-related changes in coding practices should be eliminated by study of MC data. Nationally in 2020, MC cancer mortality rose by only 3% over a pre-pandemic baseline, corresponding to ~13,600 excess deaths. Mortality elevation was measurably higher for less deadly cancers (breast, colorectal, and hematological, 2–7%) than cancers with a poor survival rate (lung and pancreatic, 0–1%). In comparison, there was substantial elevation in MC deaths from diabetes (37%) and Alzheimer’s (19%). To understand these differences, we simulated the expected excess mortality for each condition using COVID-19 attack rates, life expectancy, population size, and mean age of individuals living with each condition. We find that the observed mortality differences are primarily explained by differences in life expectancy, with the risk of death from deadly cancers outcompeting the risk of death from COVID-19.